Read full article 24 November 2020, 5:29 am·2-min read FILE PHOTO: Media tour at Chinese vaccine maker Sinovac Biotech in Beijing SAO PAULO (Reuters) - Brazil has gathered enough infection data from a late-stage trial of an experimental COVID-19 vaccine developed by China's Sinovac Biotech and expects to have interim results on its efficiency in early December, trial organizers said on Monday. Dimas Covas, director of Butantan biomedical research institute that is running the late-stage trial of the Sinovac vaccine in Brazil,...
Full ArticleBrazil has enough infection data to analyze Sinovac's COVID-19 vaccine - officials
WorldNews
0 shares
1 views
You might like
Related news coverage
Trials show third COVID-19 vaccine is cheaper, effective
AstraZeneca said on Monday that late-stage trials showed its coronavirus vaccine was up to 90 per cent effective, giving public..
Mid-Day